404 related articles for article (PubMed ID: 29406241)
21. Immunogenicity of a fusion protein containing PilQ and disulphide turn region of PilA from Pseudomonas aeruginosa in mice.
Gholami M; Chirani AS; Razavi S; Falak R; Irajian G
Lett Appl Microbiol; 2017 Nov; 65(5):439-445. PubMed ID: 28857243
[TBL] [Abstract][Full Text] [Related]
22. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies.
Finke M; Muth G; Reichhelm T; Thoma M; Duchêne M; Hungerer KD; Domdey H; von Specht BU
Infect Immun; 1991 Apr; 59(4):1251-4. PubMed ID: 1706316
[TBL] [Abstract][Full Text] [Related]
23. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
[TBL] [Abstract][Full Text] [Related]
24. Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection.
Gilleland HE; Gilleland LB; Staczek J; Harty RN; García-Sastre A; Palese P; Brennan FR; Hamilton WD; Bendahmane M; Beachy RN
FEMS Immunol Med Microbiol; 2000 Apr; 27(4):291-7. PubMed ID: 10727884
[TBL] [Abstract][Full Text] [Related]
25. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
Zaidi TS; Priebe GP; Pier GB
Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
[TBL] [Abstract][Full Text] [Related]
26. DNA vaccines against chronic lung infections by Pseudomonas aeruginosa.
Staczek J; Gilleland LB; van der Heyde HC; Gilleland HE
FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):147-53. PubMed ID: 12832118
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M
Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242
[TBL] [Abstract][Full Text] [Related]
28. Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.
Krause A; Whu WZ; Xu Y; Joh J; Crystal RG; Worgall S
Vaccine; 2011 Mar; 29(11):2131-9. PubMed ID: 21215829
[TBL] [Abstract][Full Text] [Related]
29. Conjugation of alginate to a synthetic peptide containing T- and B-cell epitopes as an induction for protective immunity against Pseudomonas aeruginosa.
Farjaha A; Owlia P; Siadat SD; Mousavi SF; Shafieeardestani M
J Biotechnol; 2014 Dec; 192 Pt A():240-7. PubMed ID: 25449544
[TBL] [Abstract][Full Text] [Related]
30. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
[TBL] [Abstract][Full Text] [Related]
31. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
[TBL] [Abstract][Full Text] [Related]
32. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Pier G
Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
[TBL] [Abstract][Full Text] [Related]
33. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
[TBL] [Abstract][Full Text] [Related]
34. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
35. Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa.
Farjah A; Owlia P; Siadat SD; Mousavi SF; Ardestani MS; Mohammadpour HK
APMIS; 2015 Feb; 123(2):175-83. PubMed ID: 25470757
[TBL] [Abstract][Full Text] [Related]
36. Nasal immunization with Burkholderia multivorans outer membrane proteins and the mucosal adjuvant adamantylamide dipeptide confers efficient protection against experimental lung infections with B. multivorans and B. cenocepacia.
Bertot GM; Restelli MA; Galanternik L; Aranibar Urey RC; Valvano MA; Grinstein S
Infect Immun; 2007 Jun; 75(6):2740-52. PubMed ID: 17296759
[TBL] [Abstract][Full Text] [Related]
37. Immunization with Bivalent Flagellin Protects Mice against Fatal
Behrouz B; Hashemi FB; Fatemi MJ; Naghavi S; Irajian G; Halabian R; Imani Fooladi AA
J Immunol Res; 2017; 2017():5689709. PubMed ID: 29201922
[No Abstract] [Full Text] [Related]
38. Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in mice.
Roier S; Leitner DR; Iwashkiw J; Schild-Prüfert K; Feldman MF; Krohne G; Reidl J; Schild S
PLoS One; 2012; 7(8):e42664. PubMed ID: 22880074
[TBL] [Abstract][Full Text] [Related]
39. Outer-Membrane-Vesicle-Associated O Antigen, a Crucial Component for Protecting Against
Bottero D; Zurita ME; Gaillard ME; Carriquiriborde F; Martin Aispuro P; Elizagaray M; Bartel E; Castuma C; Hozbor D
Front Immunol; 2018; 9():2501. PubMed ID: 30459769
[No Abstract] [Full Text] [Related]
40. Pseudomonas aeruginosa Leucine Aminopeptidase Influences Early Biofilm Composition and Structure via Vesicle-Associated Antibiofilm Activity.
Esoda CN; Kuehn MJ
mBio; 2019 Nov; 10(6):. PubMed ID: 31744920
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
